$IMRX
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
Healthcare
Sector
Biotechnology
Industry
Benjamin J. Zeskind
CEO
54
Employees
$5.02
Current Price
$190.59M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 months | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 3 months | Buys | 5 | 5 | $234,342.66 | 51,819 | All Buys |
| Sells | 0 | 0 | - | - | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Jan 16, 2026 | Brakewood Harold Eugene Chief Business Officer | Purchase | 5,250 | $4.76 | $24,990.00 | View Details |
| Jan 15, 2026 | Schall Thomas J. Director | Purchase | 21,645 | $4.67 | $101,041.02 | View Details |
| Jan 15, 2026 | Hall Brett Matthew CHIEF SCIENTIFIC OFFICER | Purchase | 2,298 | $4.57 | $10,501.86 | View Details |
| Jan 13, 2026 | Neufeld Leah R CHIEF PEOPLE OFFICER | Purchase | 2,626 | $4.15 | $10,905.78 | View Details |
| Jan 12, 2026 | Feinberg Peter Director | Purchase | 20,000 | $4.35 | $86,904.00 | View Details |
18 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
Estimated-$0.31
ActualN/A
Revenue
EstimatedN/A
ActualN/A
3 more earnings records available โ create a free account to see 12 months of history
Related Activity
Cross-company insider connections and cluster buy signals